Sciences Humaines et Sociales PAIRS-AJA (IC2017-10) Impact of Sick Peer Relation on the Adaptation to Disease and on Treatment of Cancer-suffering Adolescents and Young Adults (PEERS-AYA) Paris VALERIE LAURENCE
Appareil pulmonaire CheckMate 592 (CA209-592) Protocol Title: An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC). Paris NICOLAS GIRARD
Appareil pulmonaire DICIPLE (IFCT-1701) A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment Paris, Saint-Cloud
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Appareil pulmonaire CANOPY-1 (CACZ885U2301) A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1) Paris
Appareil pulmonaire BP40657 A TWO-PART PHASE Ib/II STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS IN PATIENTS WITH STAGE IV;NONÀSMALL CELL LUNG CANCER Paris
Appareil pulmonaire ENTREE-LUNG (GSK 205801) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants Paris NICOLAS GIRARD
Appareil pulmonaire EDI-1001 Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Pédiatrie Hématologie EURONET-PHL-C2 European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Paris
Appareil pulmonaire MELROSE Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiological progression : the MELROSE trial Paris